Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Malus Pumila Flower is a non-standardized food allergenic extract used primarily for the diagnosis and treatment of hypersensitivity to apple-related allergens. It belongs to the class of allergenic extracts used in clinical immunology.
Name
Malus Pumila Flower
Raw Name
MALUS PUMILA FLOWER
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Malus Pumila Flower
Malus Pumila Flower is a non-standardized food allergenic extract used primarily for the diagnosis and treatment of hypersensitivity to apple-related allergens. It belongs to the class of allergenic extracts used in clinical immunology.
Detailed information about Malus Pumila Flower
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Malus Pumila Flower.
Malus Pumila Flower, commonly known as the blossom of the domestic apple tree, is utilized in clinical medicine as a non-standardized allergenic extract. It belongs to a specialized class of biological products known as Non-Standardized Food Allergenic Extracts [EPC]. These extracts are primarily employed by board-certified allergists and immunologists to diagnose specific IgE-mediated hypersensitivities (Type I allergies) through skin testing or to treat these allergies via allergen immunotherapy (AIT).
In the context of the Food and Drug Administration (FDA) regulatory framework, Malus Pumila Flower extracts are governed under the Center for Biologics Evaluation and Research (CBER). Unlike 'standardized' extracts (such as ragweed or grass pollen), which have a defined potency measured in Bioequivalent Allergy Units (BAU), Malus Pumila Flower is 'non-standardized.' This means its potency is typically expressed as a weight-to-volume (w/v) ratio or in Protein Nitrogen Units (PNU). This classification requires healthcare providers to exercise extreme caution when switching between different manufacturers or lots, as the biological activity may vary significantly.
Historically, allergenic extracts have been a cornerstone of allergy practice since the early 20th century. Malus Pumila Flower specifically is relevant for patients who exhibit symptoms of Oral Allergy Syndrome (OAS) or systemic fruit allergies. It is often used to identify cross-reactivity patterns, particularly the 'Birch-Apple Syndrome,' where patients sensitized to birch pollen (Bet v 1) experience allergic reactions to the Mal d 1 protein found in the Malus species.
The mechanism of action for Malus Pumila Flower extract depends on whether it is being used for diagnostic or therapeutic purposes.
For diagnostic use (skin prick or intradermal testing), the extract contains the specific proteins (allergens) found in the apple flower. When introduced into the epidermis or dermis of a sensitized individual, these allergens bind to specific IgE (Immunoglobulin E) antibodies that are already attached to the surface of mast cells and basophils. This binding causes 'cross-linking' of the IgE receptors, triggering degranulation. During degranulation, the cells release inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This results in a localized 'wheal and flare' reaction (a raised bump and surrounding redness), which the clinician measures to confirm the presence of an allergy.
For therapeutic use (allergen immunotherapy), the mechanism is more complex and involves 'immunological desensitization.' By administering gradually increasing doses of the Malus Pumila Flower extract via subcutaneous injection, the patient's immune system undergoes a shift. This shift typically involves a transition from a Th2-biased response (which promotes IgE production and allergic inflammation) to a Th1-biased or T-regulatory (Treg) response. This process increases the production of 'blocking antibodies' (IgG4), which compete with IgE for allergen binding, thereby preventing the allergic cascade upon subsequent natural exposure.
Traditional pharmacokinetic studies (absorption, distribution, metabolism, and excretion) are not typically conducted for allergenic extracts like Malus Pumila Flower, as they are biological mixtures rather than discrete chemical entities. However, the following immunological 'kinetics' apply:
Malus Pumila Flower extract is primarily indicated for:
> Important: Only your healthcare provider can determine if Malus Pumila Flower is right for your specific condition. The use of allergenic extracts must be supervised by a clinician prepared to manage anaphylaxis.
Dosage for Malus Pumila Flower is highly individualized and must be determined by an allergy specialist based on the patient's clinical history and sensitivity levels. There is no 'standard' dose for non-standardized extracts.
Malus Pumila Flower is not typically recommended for infants under the age of 2, as the immune system is still developing and skin reactivity may be inconsistent. For children over 2, the diagnostic procedure is identical to adults, though the number of tests performed in one session may be limited to reduce discomfort. Immunotherapy in children requires careful monitoring of growth and potential systemic reactions.
No specific dose adjustments are provided in the manufacturer's labeling for renal impairment. However, since the clearance of inflammatory mediators is essential, patients with end-stage renal disease should be monitored closely for prolonged reactions.
No dose adjustments are required for hepatic impairment, as the liver does not play a primary role in the metabolism of protein-based allergenic extracts.
In elderly patients, skin reactivity may be diminished (reduced wheal and flare response). Clinicians should consider this 'false negative' risk. Additionally, elderly patients are more likely to be on beta-blockers, which is a significant precaution for any allergenic extract use.
This medication is NEVER self-administered at home for diagnostic purposes. It must be administered in a clinical setting.
In the context of immunotherapy, a missed dose requires a 'step-back' in dosage. If a dose is missed by more than one week, the allergist may repeat the previous dose. If missed by several weeks, the dose may need to be reduced significantly to prevent a systemic reaction during the 're-introduction' phase.
An overdose of Malus Pumila Flower extract (either too high a concentration in testing or an incorrect volume in therapy) can lead to a massive release of histamine.
Immediate administration of intramuscular epinephrine (0.3mg for adults) is the primary treatment. Supportive care with oxygen, IV fluids, and antihistamines should follow in an emergency department.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing testing or treatment with Malus Pumila Flower will experience localized reactions. These are generally considered expected pharmacological effects of the extract.
> Warning: Stop taking Malus Pumila Flower and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
Prolonged use of allergenic extracts in immunotherapy is generally well-tolerated. However, some patients may develop a persistent 'late-phase' inflammatory response at the injection site. There is no evidence that long-term use of Malus Pumila Flower extract leads to autoimmune disease or malignancy.
While Malus Pumila Flower specifically may not have a unique black box warning, the FDA requires a Class Black Box Warning for all allergenic extracts.
Report any unusual symptoms to your healthcare provider.
Malus Pumila Flower extract is a potent biological substance. It must only be used by clinicians who are experts in the diagnosis and treatment of allergic diseases. Patients must be screened for current health status before every administration. For example, if a patient is currently experiencing an asthma flare or a severe viral infection, the administration of the extract should be postponed to avoid priming the immune system for a systemic reaction.
No specific individual black box warning exists for Malus Pumila Flower, but it falls under the general FDA mandate for allergenic extracts: "WARNING: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes. Epinephrine must be available."
Malus Pumila Flower does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they are fully recovered and cleared by a physician.
Alcohol consumption should be avoided on the day of testing or immunotherapy. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially trigger a more severe reaction.
If a patient experiences a Grade 3 or 4 systemic reaction (anaphylaxis), the clinician will perform a risk-benefit analysis. In many cases, the extract is discontinued, or the dose is drastically reduced and the build-up phase restarted with extreme caution.
> Important: Discuss all your medical conditions with your healthcare provider before starting Malus Pumila Flower.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Patients allergic to Malus Pumila Flower are highly likely to be cross-sensitive to other members of the Rosaceae family (including Malus domestica fruit, Prunus persica/Peach, and Prunus avium/Cherry). There is also a very high rate of cross-sensitivity with Birch Pollen (Betula verrucosa) due to the structural similarity between the Mal d 1 and Bet v 1 proteins.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Malus Pumila Flower.
FDA Category C: Animal reproduction studies have not been conducted with Malus Pumila Flower extract. It is also not known whether the extract can cause fetal harm when administered to a pregnant woman. The primary concern is not the extract itself, but the potential for a systemic reaction (anaphylaxis) in the mother. Anaphylaxis causes a sudden drop in maternal blood pressure, which can lead to placental insufficiency and fetal distress.
Clinical Guidance: Immunotherapy build-up should be suspended during pregnancy. Maintenance therapy may be continued if the benefit of controlling severe allergic symptoms outweighs the risk of a reaction.
It is not known whether the allergenic components of Malus Pumila Flower are excreted in human milk. However, because these are large proteins that are likely digested in the infant's gut, the risk to the nursing child is considered low. The decision to continue therapy while breastfeeding should be made based on the mother's clinical need.
Safety and effectiveness in children under the age of 2 have not been established. In older children, Malus Pumila Flower is used for diagnosis, but clinicians must be mindful of the psychological impact of skin testing and the risk of systemic reactions. Children with a history of severe asthma require particularly close monitoring.
Clinical studies of Malus Pumila Flower did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, older adults often have comorbidities (like heart disease) or are taking medications (like beta-blockers) that make the use of allergenic extracts riskier. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.
There are no specific guidelines for Malus Pumila Flower in renal impairment. Since the proteins are degraded into amino acids, significant accumulation is unlikely. However, the patient's ability to handle the physiological stress of a potential reaction should be assessed.
Hepatic impairment does not significantly affect the processing of allergenic extracts. No specific dose adjustments are required for patients with liver disease.
> Important: Special populations require individualized medical assessment.
Malus Pumila Flower extract acts as a specific antigen that interacts with the adaptive immune system. The primary active components are proteins, most notably the Mal d 1 allergen (a PR-10 protein) and potentially Mal d 3 (a lipid transfer protein).
| Parameter | Value |
|---|---|
| Bioavailability | Low (Local/Subcutaneous) |
| Protein Binding | N/A (Protein-based) |
| Half-life | Hours (Allergen) / Years (Immune Memory) |
| Tmax | 15-30 minutes (Local absorption) |
| Metabolism | Proteolysis by tissue enzymes |
| Excretion | Renal (as peptide fragments) |
Malus Pumila Flower is classified as a Non-Standardized Food Allergenic Extract. It belongs to the broader therapeutic category of Biologicals / Immunomodulators. It is related to other fruit-based extracts like Prunus persica (Peach) and Pyrus communis (Pear) extracts.
Medications containing this ingredient
Common questions about Malus Pumila Flower
Malus Pumila Flower extract is primarily used by allergy specialists as a diagnostic tool to identify if a person has a specific allergy to apple blossoms or related apple proteins. It is applied during skin prick testing, where a small amount of the extract is introduced into the skin to see if a 'wheal and flare' reaction occurs. In some specialized clinical settings, it may also be used as part of an allergen immunotherapy program to help desensitize the patient's immune system over time. This is particularly relevant for individuals who suffer from severe cross-reactivity between tree pollens and fruits. It is not a treatment for acute allergic reactions and should never be used to treat an ongoing anaphylactic event.
The most common side effects are localized to the site where the extract was applied or injected. These include itching, redness, and a raised bump known as a wheal, which typically appears within 20 minutes of a skin test. Some patients may also experience a 'late-phase' reaction, where the area becomes swollen and warm several hours later. If used in immunotherapy injections, a small lump or bruise may form at the injection site. Systemic side effects like tiredness or a mild headache are less common but can occur. Most local reactions resolve on their own within 24 hours without the need for intensive medical treatment.
It is strongly advised to avoid alcohol on the day you receive a Malus Pumila Flower skin test or immunotherapy injection. Alcohol acts as a vasodilator, meaning it widens your blood vessels, which can speed up the absorption of the allergen into your bloodstream. This increased absorption rate can raise the risk of a systemic allergic reaction or even anaphylaxis. Furthermore, alcohol can mask the early symptoms of a reaction, such as dizziness or flushing, making it harder for you or your doctor to recognize an emergency. Always wait at least 24 hours after your appointment before consuming alcoholic beverages.
The safety of Malus Pumila Flower during pregnancy has not been established through rigorous clinical trials, placing it in FDA Category C. The main concern for pregnant women is not the extract itself, but the risk of a severe allergic reaction (anaphylaxis) following its use. Anaphylaxis can cause a dangerous drop in the mother's blood pressure, which reduces the amount of oxygen reaching the fetus. Consequently, most allergists will not start a new course of allergy testing or immunotherapy during pregnancy. If a woman is already on a stable maintenance dose of immunotherapy, her doctor may choose to continue it, but the dose is rarely increased until after delivery.
If you are using Malus Pumila Flower for diagnostic skin testing, the results are almost immediate, usually appearing within 15 to 20 minutes. However, if it is being used for therapeutic desensitization (immunotherapy), the process is much slower. Most patients do not notice a significant reduction in their allergy symptoms until they have reached their 'maintenance dose,' which typically takes 3 to 6 months of weekly injections. Full clinical benefit often requires 12 months of consistent treatment. A complete course of therapy usually lasts 3 to 5 years to ensure long-term changes in the immune system's response to the allergen.
Yes, you can stop taking Malus Pumila Flower extracts suddenly, as they do not cause physical dependence or a traditional withdrawal syndrome. However, if you are undergoing immunotherapy, stopping the treatment prematurely will likely result in the return of your original allergy symptoms over time. Your immune system will eventually lose the 'tolerance' it built up during the treatment. If you miss only one or two doses, your doctor can usually adjust your schedule to get you back on track. If you decide to stop, it is best to discuss it with your allergist to understand how it will affect your long-term allergy management plan.
If you miss a scheduled immunotherapy dose of Malus Pumila Flower, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to 'double up' on your next dose or administer it yourself. The safety of immunotherapy depends on a very specific timing and dosage escalation. If too much time passes between doses, your sensitivity to the extract may increase, making your next injection riskier. Your doctor will determine if you can receive your regular dose or if they need to temporarily reduce the dose to ensure your safety. Consistency is the key to successful allergy desensitization.
There is no clinical evidence to suggest that Malus Pumila Flower allergenic extracts cause weight gain. These extracts are proteins that work specifically on the immune system and do not interfere with metabolic rate, appetite, or fat storage. Unlike systemic corticosteroids, which are sometimes used to treat severe allergies and are known to cause weight gain, allergenic extracts are administered in very small quantities. If you experience unexpected weight changes while undergoing allergy treatment, you should consult your healthcare provider to investigate other potential causes, such as lifestyle changes, other medications, or underlying health conditions.
Malus Pumila Flower can interact with several types of medications, particularly those that affect your body's response to an allergic reaction. Antihistamines must be stopped several days before skin testing because they will block the reaction and lead to false results. More importantly, medications like beta-blockers can make it very difficult to treat a serious reaction if one occurs, as they block the action of emergency epinephrine. Tricyclic antidepressants and MAO inhibitors can also complicate the treatment of an allergic emergency. Always provide your allergist with a complete and updated list of all medications, including over-the-counter drugs and herbal supplements.
The concept of 'generic' drugs does not apply to allergenic extracts in the same way it does to chemical pills. Malus Pumila Flower is a biological product, and various manufacturers may produce their own versions of the extract. However, because these are 'non-standardized,' one manufacturer's extract may be stronger or weaker than another's, even if the label says the same concentration (e.g., 1:20 w/v). Therefore, they are not considered 'interchangeable' like generic ibuprofen. If your doctor switches you to a different brand of extract, they will typically restart the dosing at a lower level to ensure you do not have an adverse reaction to the new formulation.